Back

Cardiovascular adverse events with cdk4/6 inhibitors:a meta-analysis of randomized controlled trials

20 June 2025 (00:00 - 00:00)
Organised by: Logo
Congress Presentation Part of: Risk stratification for cancer therapy-related cardiovascular disease Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Charles Dolladille

University Hospital of Caen, Caen (France)

5 More presentations in this session

Presentation thumbnail
Non-uniform cardiovascular risks of tyrosine kinase inhibitors associated with inhibition of C-terminal Src kinase
Assistant Professor Y. Chan (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
The emerging role of left atrial strain in cardiovascular risk stratification for multiple myeloma patients undergoing carfilzomib therapy
Doctor A. Colomba (Candiolo, IT)
Abstract Slides Video
Presentation thumbnail
Machine learning modelling using cardiac magnetic resonance images to predict cancer therapy related cardiac dysfunction with external validation in HER2+ breast cancer patients
Professor P. Thavendiranathan (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Prospective evaluation of cardiac function following anti-BCMA CAR-T therapy in multiple myeloma
Doctor I. Sunayama (Nishinomiya, JP)
Abstract Slides Video
Presentation thumbnail
Cardiovascular safety of modern radiotherapy techniques in breast cancer
Mr J. Saldana Garcia (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification for cancer therapy-related cardiovascular disease

The Event

Event poster

ESC Cardio-Oncology 2025

20 June - 21 June 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources